FAPI PET/CT to predict adverse cardiac events after PCI for chronic total occlusion
Official title: The Value of FAPI Imaging for the Prediction of Adverse Cardiovascular Events in Chronic Total Occlusion of Coronary Artery Disease (FACT-2 Trial)
Run by Beijing Chao Yang Hospital · NCT07020858 · Data updated 2026-11-12
This will test whether FAPI PET/CT scans done before PCI can help predict major heart problems within 12 months in adults with chronic total coronary occlusion.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 470 (estimated) |
| Sponsor | Beijing Chao Yang Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 15, 2025 |
| Main results expected | March 15, 2026 |
| Study ends | March 15, 2027 |
| Registry record updated | June 19, 2025 |
| Trial ID | NCT07020858 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with at least one untreated CTO (reference vessel ≥2.5 mm, TIMI 0 for ≥3 months) who are eligible for PCI, willing to undergo preprocedural FAPI PET/CT, and can provide informed consent.
✕Probably not a fit
Patients with contraindications to antiplatelet therapy, severe liver dysfunction, advanced renal failure (eGFR <30), limited life expectancy (<1 year), or pregnancy are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center observational cohort of adults with at least one untreated chronic total occlusion who undergo baseline 18F-FAPI PET/CT prior to PCI and are followed for 12 months. The study will measure myocardial and plaque FAPI uptake and relate uptake levels to the incidence of major adverse cardiovascular events (MACE) after PCI. Where available, imaging features of plaque vulnerability (including OCT findings) and measures of adverse remodeling will be compared with FAPI signals. The goal is to determine whether noninvasive FAPI imaging provides prognostic information beyond standard clinical and angiographic data.
Why it matters
Potential benefit: If successful, FAPI PET/CT could identify CTO patients at higher risk of adverse events after PCI so clinicians can tailor follow-up and management.
How similar studies have gone: Preliminary data (the original FACT study) showed FAPI imaging may predict ventricular remodeling at 6 months, but long-term prognostic value and plaque-vulnerability correlations remain incompletely established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Confirmed diagnosis of ≥1 untreated chronic total occlusion (CTO):Defined as complete occlusion of a major coronary artery or relevant collateral (reference vessel diameter ≥2.5 mm or confirmed by two independent interventional cardiologists), with TIMI flow grade 0 in the distal segment and duration ≥3 months.Preoperatively confirmed by coronary angiography or coronary computed tomography angiography (CTCA). 3. Willingness to undergo FAPI-PET imaging and receive PCI under imaging guidance. 4. Ability to provide written informed consent. Exclusion Criteria: 1. Contraindications to antiplatelet therapy: Allergy or intolerance to aspirin, clopidogrel, or ticagrelor. 2. Severe liver dysfunction: Liver function parameters exceeding 3× the upper limit of normal. 3. Severe chronic kidney disease: Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m². 4. Life expectancy \<1 year due to non-cardiovascular comorbidities. 5. Pregnancy or women of childbearing potential (unless surgically sterile or using contraception).
Where it's running
-
Beijing Chaoyang Hospital,Capital Medical University,Beijing,China
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Lin Zhao, Dr — Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
- Study coordinator: Shengwen Yang, Dr
- Email: verayang1990@163.com
- Phone: +8601085231480
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Common femoral vein-to-artery diameter ratio to detect elevated LVEDP
Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease
In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.
-
IVUS-Guided Left Main Stenting: IVUS-Guided vs Trained-Eye Approach
This trial tests whether using IVUS to guide left main bifurcation stenting is as good as using an angiography-driven, experience-based approach by an IVUS-savvy operator.
-
Can CZT-SPECT/CT quantify myocardial tracer uptake to match PET measurements in coronary artery disease?
This study tests whether CZT-SPECT/CT can quantify heart blood flow at rest and stress and see if the results align with PET measurements for people with coronary artery disease.
-
Ultrasound vs CT calcium scoring to reclassify symptomatic chest pain
This study tests whether carotid ultrasound can reclassify risk in adults with chest pain and suspected chronic coronary syndrome, compared with the CT calcium score.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.